Business Wire

Nearly Three Quarters of U.S. Travellers Support the Introduction of International Vaccine Passports, According to OAG Research

13.9.2021 16:00:00 EEST | Business Wire | Press release

Share

Travellers are taking to the skies again, but the immediate future of air travel remains highly turbulent, according to OAG’s survey of 1,800-plus U.S. travellers in July and August. Domestic capacity in the U.S. is up 81% from June – August 2021, compared to the same period last year. The increase is being fuelled by strong consumer demand; 70% of consumers surveyed by OAG have booked flights for the future.

While travellers’ willingness to fly is increasing, the Delta variant, increased COVID transmission rates and vaccination preferences weigh heavily on the near and mid-term outlook. The large majority of consumers surveyed by OAG report being fully vaccinated. However, OAG found that only 15% of non-vaccinated individuals plan to get vaccinated before their next trip.

Many airlines and destinations are considering vaccine mandates to strengthen confidence and fight transmission. Sixty-eight percent of all survey respondents said they are interested in or want domestic vaccine passports, and 70% believe vaccine passports should be required for international travel. Alarmingly, of those that said they were not yet vaccinated, 56% said they still wouldn’t get vaccinated even if the airline, airport, or destination required it to travel.

“Vaccine mandates are a polarizing issue. Many airlines, governments and destinations are actively considering mandating vaccines to fly or enter, and the majority of travellers support the use of vaccine passports,” said John Grant, senior analyst at OAG. “While this may add fuel to hot fire, the ongoing strength and resilience of the entire travel market is directly linked to higher vaccination levels and lower transmission rates.”

Other takeaways from OAG’s research include:

  • Continued COVID-19 concerns keep some travellers grounded. Of the 30% of respondents who haven’t booked flights yet, 40% are waiting for vaccination rates and regulations to improve and 30% are waiting for vaccine passports to be required.
  • The business travel outlook remains cloudy. Only 62% of business travellers said their company is planning air travel in the next 12 months, while 38% said their company either has no plans (20%) or has not specified plans (18%).
  • Holiday travel expected to bounce back. The 2021 holiday travel season projects to be a lot stronger than 2020. Of the 38% of travellers surveyed by OAG that said they typically fly for the holidays, only 40% of this group did so in 2020. This year, the percentage of that group who do intend to fly more than doubled (85%). Planned capacity for Thanksgiving week tells a similar story, currently with 47% more domestic seats booked than last year.
  • Booking behaviour remains erratic. Nearly half of travellers surveyed are still booking on short notice (between two weeks to a month in advance), and half are booking between two-six-plus months out. Eighty-eight percent expect ticket prices to rise in the next 12 months.

For the full survey insights, view the report here, https://www.oag.com/us-traveler-survey. To learn more about OAG, visit https://www.oag.com/.

About OAG

OAG is a leading global travel data provider, that has been powering the growth and innovation of the air travel ecosystem since 1929. Headquartered in the UK, OAG has global operations in the USA, Singapore, Japan, Lithuania and China. For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chrissy Azevedo
Corporate Ink for OAG
pressoffice@oag.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye